Metabolic & Fat Loss FDA Approved

Dulaglutide

Also known as: Trulicity, Dulaglutida

Overview

Long-acting GLP-1 receptor agonist composed of a GLP-1 analog fused to a modified IgG4 immunoglobulin Fc fragment. This fusion protein confers an extended half-life of approximately 5 days, enabling weekly administration. Approved for type 2 diabetes treatment and cardiovascular risk reduction in diabetic patients.

FDA-approved as Trulicity (2014) for type 2 diabetes treatment, including cardiovascular risk reduction in diabetic patients, demonstrated in the REWIND study.

Fusion protein (~59.7 kDa) — GLP-1 analog fused with IgG4 Fc fragment

Half-life

~5 days

Administration Route

Subcutaneous

Category

Metabolic & Fat Loss

Mechanism of Action

  • GLP-1 receptor agonism with glucose-dependent insulin secretion stimulation
  • Suppression of glucagon secretion in hyperglycemic states
  • Delayed gastric emptying
  • Appetite and caloric intake reduction via hypothalamic signaling
  • Improved insulin sensitivity in peripheral tissues
  • Cardiovascular protection with reduction of major adverse cardiovascular events (MACE)

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 0.75-4.5 mg per week (subcutaneous)
Frequency Once weekly
Timing Same day of the week, any time of day, regardless of meals
Duration Continuous use (with gradual dose escalation)

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Decreased appetite
  • Fatigue

Presentations & Preparation

Vials of Dulaglutide found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Not applicable — pre-filled pen ready for use
  • Volume: Single-dose pre-filled pen (0.5 ml)
  • Use single-dose pre-filled pen — no reconstitution required
  • Inject subcutaneously in abdomen, thigh or arm, rotating sites
  • Dose escalation every 4 weeks (0.75 → 1.5 → 3.0 → 4.5 mg)
  • Each pen is single-use — discard after administration

Storage

  • Lyophilized: Not applicable — ready-to-use solution
  • Reconstituted: Refrigerated 2-8°C (unopened); room temperature up to 14 days (maximum 30°C)
  • Do not freeze — discard if frozen
  • Protect from direct light
  • Keep in original packaging until time of use
Reconstitution Calculator

Scientific Studies

Published studies on Dulaglutide.

Related Peptides